Clinical Trials Sponsored by XOMA (US) LLC

Total 120 results

XOMA (US) LLC

Terminated

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States, Australia, Canada
XOMA (US) LLC

Completed

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States
XOMA (US) LLC

Suspended

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

United States
XOMA (US) LLC

Completed

Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand

Osteoarthritis

United States
XOMA (US) LLC

Completed

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Osteoarthritis

United States
XOMA (US) LLC

Completed

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
XOMA (US) LLC

Completed

Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas

Adenocarcinoma

United States
XOMA (US) LLC

Completed

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery (XOMA 358)

Hypoglycemia

United States
XOMA (US) LLC

Completed

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United Kingdom, United States
XOMA (US) LLC

Terminated

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data (EYEGUARD™-E)

Uveitis

United States
XOMA (US) LLC

Completed

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Osteoarthritis

United States
XOMA (US) LLC

Completed

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Acne Vulgaris

United States
XOMA (US) LLC

Terminated

Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (HSCT)

Graft Versus Host Disease

United States
XOMA (US) LLC

Completed

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Type 2 Diabetes Mellitus

United States
XOMA (US) LLC

Terminated

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States
XOMA (US) LLC

Terminated

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States, Australia, Canada
XOMA (US) LLC

Terminated

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis (EYEGUARD™-US)

Behcet's Disease Uveitis

United States
XOMA (US) LLC

Completed

Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Mexico
XOMA (US) LLC

Completed

Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus

Type 2 Diabetes

Switzerland
XOMA (US) LLC

Completed

Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis

Psoriatic Arthritis
XOMA (US) LLC

Completed

Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.

Rheumatoid Arthritis

United States
Novartis Pharmaceuticals
XOMA (US) LLC

Completed

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States, Belgium, Canada, Italy, France, Hong Kong, Australia, United Kingdom, Singapore, Korea, Republic of, Germany
University of Zurich
XOMA (US) LLC

Completed

Effects of XOMA 052 on Insulin Production in Type 1 Diabetes (LATE STAGE)

Diabetes Mellitus Type 1

Switzerland
Novartis Pharmaceuticals
XOMA (US) LLC

Terminated

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Chronic Lymphocytic Leukemia

United States
XOMA (US) LLC
Juvenile Diabetes Research Foundation

Completed

Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes

Type 1 Diabetes

Switzerland
XOMA (US) LLC
Institut de Recherches Internationales Servier

Terminated

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis (EYEGUARD™-A)

Uveitis

United States, France, Germany, Poland, United Kingdom, China, Spain, Mexico, Portugal, Turkey, Israel, Korea, Republic of, South Africa, Taiwan, Argentina, Brazil, Austria, Russian Federation, Australia, Armenia, Greece, Tunisia
XOMA (US) LLC
Institut de Recherches Internationales Servier

Terminated

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment (EYEGUARD™-C)

Uveitis

United States, France, Germany, Poland, United Kingdom, China, Spain, Mexico, Portugal, Turkey, Israel, Canada, South Africa, Taiwan, Argentina, Russian Federation, Australia, Italy, Brazil, Armenia, Greece, Tunisia
Curium US LLC

Active, not recruiting

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Metastasis From Malignant Tumor of Prostate

United States, France, Spain, Italy
US CosmeceuTechs, LLC

Completed

Tolerability and Efficacy of Anti-Aging Treatment Regimen in Subjects With Photodamage

Skin Manifestations
Curium US LLC

Not yet recruiting

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur)

Prostate Cancer | Prostate Adenocarcinoma | Biochemical Recurrence of Malignant Neoplasm of Prostate
Curium US LLC

Not yet recruiting

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer (Solar-Stage)

Prostate Cancer | Prostate Adenocarcinoma
Amivas (US), LLC

Recruiting

Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants

Pregnancy | Malaria

United States
Curium US LLC

Completed

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

Metastasis From Malignant Tumor of Prostate (Disorder)

United States
Curium US LLC

Approved for marketing

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Neuroendocrine Tumors
Kira Pharmacenticals (US), LLC.

Not yet recruiting

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Kira Pharmacenticals (US), LLC.

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Paroxysmal Nocturnal Hemoglobinuria

Australia
Osmotica Pharmaceutical US LLC

Completed

Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease

Parkinson's Disease

Argentina
Aphaia Pharma US LLC

Recruiting

A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation (APHD-012) in Subjects With a Pathological Oral Glucose Tolerance Test (OGTT)

PreDiabetes | Glucose Tolerance Impaired

Slovakia
Kira Pharmacenticals (US), LLC.

Not yet recruiting

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

Glomerulonephritis
Aphaia Pharma US LLC

Recruiting

A Study of Distal Jejunal-release Dextrose in Obese Participants

Obese

Germany, Puerto Rico
Kira Pharmacenticals (US), LLC.

Not yet recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104

Paroxysmal Nocturnal Hemoglobinuria

China
NanOlogy, LLC
US Biotest, Inc.

Available

Expanded Access to NanoDoce

Urogenital Neoplasms
NanOlogy, LLC
US Biotest, Inc.

Completed

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Cancer | Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Urinary Bladder Neoplasm | Cancer of the Bladder | Malignant Tumor of the Urinary Bladder

United States
NanOlogy, LLC
US Biotest, Inc.

Active, not recruiting

Trial of NanoPac Intratumoral Injection in Lung Cancer

Lung Cancer | Lung Cancer, Nonsmall Cell | Neoplasm of Lung | Lung Cancer, Small Cell

United States
NanOlogy, LLC
US Biotest, Inc.

Completed

Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

Pancreatic Mucinous-Cystic Neoplasm

United States
NanOlogy, LLC
US Biotest, Inc.

Terminated

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Ovarian Carcinoma

United States
NanOlogy, LLC
US Biotest, Inc.

Completed

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

Adenocarcinoma of the Prostate

United States
USWM, LLC (dba US WorldMeds)

Completed

Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction

Substance Withdrawal Syndrome | Opiate Dependence | Opiate Addiction

United States
NanOlogy, LLC
US Biotest, Inc.

Available

Expanded Access to NanoPac
NanOlogy, LLC
US Biotest, Inc.

Completed

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Locally Advanced Pancreatic Adenocarcinoma

United States

Clinical Trials Sponsored by XOMA (US) LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations